CB1-IN-1 (also known as DBPR211) is a novel, potent, peripherally restricted antagonist of the CB1R (cannabinoid 1 receptor) with Ki values of 0.3 nM and 21 nM for CB1R (EC50 of 3 nM) and CB2R, respectively. CB1-IN-1 has demonstrated notable effects on weight loss and can reduce insulin resistance and hepatic steatosis in a diet-induced obese mice modea model of diet-induced obesity in mice. It therefore has a great deal of potential for use in metabolic syndromes related to obesity. Additionally, it has favorable PK profiles, such as a very low brain to plasma ratio that indicates a low likelihood of BBB crossing.
Physicochemical Properties
| Molecular Formula | C33H31CL2F3N6O3S2 | |
| Molecular Weight | 751.67 | |
| Exact Mass | 750.122 | |
| Elemental Analysis | C, 52.73; H, 4.16; Cl, 9.43; F, 7.58; N, 11.18; O, 6.39; S, 8.53 | |
| CAS # | 1429239-98-4 | |
| Related CAS # |
|
|
| PubChem CID | 71515460 | |
| Appearance | White to off-white solid powder | |
| Density | 1.5±0.1 g/cm3 | |
| Index of Refraction | 1.672 | |
| LogP | 6.52 | |
| Hydrogen Bond Donor Count | 2 | |
| Hydrogen Bond Acceptor Count | 11 | |
| Rotatable Bond Count | 10 | |
| Heavy Atom Count | 49 | |
| Complexity | 1310 | |
| Defined Atom Stereocenter Count | 0 | |
| SMILES | ClC1C=C(C=CC=1N1C(C2=CC=C(C#CC3C=CC(C(F)(F)F)=CC=3)S2)=C(C(C(NN2CCCCC2)=O)=N1)CNS(N1CCCC1)(=O)=O)Cl |
|
| InChi Key | KAIYFJUWIBTYPK-UHFFFAOYSA-N | |
| InChi Code | InChI=1S/C33H31Cl2F3N6O3S2/c34-24-11-14-28(27(35)20-24)44-31(29-15-13-25(48-29)12-8-22-6-9-23(10-7-22)33(36,37)38)26(21-39-49(46,47)43-18-4-5-19-43)30(40-44)32(45)41-42-16-2-1-3-17-42/h6-7,9-11,13-15,20,39H,1-5,16-19,21H2,(H,41,45) | |
| Chemical Name | 1-(2,4-dichlorophenyl)-N-piperidin-1-yl-4-[(pyrrolidin-1-ylsulfonylamino)methyl]-5-[5-[2-[4-(trifluoromethyl)phenyl]ethynyl]thiophen-2-yl]pyrazole-3-carboxamide | |
| Synonyms |
|
|
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
[1]. Discovery of 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor anta. |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3304 mL | 6.6519 mL | 13.3037 mL | |
| 5 mM | 0.2661 mL | 1.3304 mL | 2.6607 mL | |
| 10 mM | 0.1330 mL | 0.6652 mL | 1.3304 mL |